LeadDiscovery Custom Reports

Monday November 09 2009 | Biotechnology feed | All feeds

Custom Reports
Return to introduction on drug discovery ~ LeadDiscovery Reports

"Which pharmacological targets should our R&D groups be considering?"...Which disease groups should our therapeutic candidates be indicated for?" These are common types of questions in the rapidly moving drug development industry. Can your company provide reliable answers without placing serious demands on in house resources? For the past 3 years analysts at LeadDiscovery have been using their pharmaceutical experience to produce DiscoveryDossiers in order to streamline preclinical decision making. Upto 50 DiscoveryDossiers are now being produced each year and almost all the major pharmaceutical companies have found these reports to be of use to their R&D efforts. Reports are designed to help industrial researchers select new drug discovery targets, upper management to make strategic decisions regarding research direction, investors and licensing personnel to assess new business prospects. Reports have even been used by academic institutions to develop their research into therapeutic candidates. Can you afford to wait for the publication of a DiscoveryDossiers that meets your requirements? If not CustomReports may be for you. Each report may include one or more of the following topics: Disease Profiling Expert opinions on proof of concept/target identification Detailed analysis of development activity Market Analysis and time-lines Strategic direction and screening architecture Request further details Price range: $1,500-$5,000 depending on exclusivity and content
Disease profiling. When moving into a new therapeutic arena it is important to have a clear understanding of clinical issues. How high is disease prevalence? What is the impact of the disease? Which treatment options are available? Do therapeutic strategies meet clinical demands? By tapping into various clinical resources and extracting relevant information we will be able to deliver disease profiles that provide you with clear answers to these key questions.
Case study 1 (an extract from "Pharmaceutical approaches to COPD") click here

Expert opinions on proof of concept. Your company is considering a new therapeutic area but you are unsure of which pharmacological targets to select. Or, perhaps you have a therapeutic candidate that you would like to develop for a new indication but you are unsure how successful this is likely to be. These are further issues that are central to new drug discovery efforts. Whatever your area of interest, our pharmaceutical analysts working in collaboration with opinion leaders will provide, through CustomReports, a thorough state of the art review of your selected area.
Case study 2 (an extract from "Male and female sexual dysfunction") click here

Detailed analysis of development activity: Successful drug development is all about identifying a niche. For example, there are currently few effective treatments of COPD and development activity remains slow. Consequently new COPD treatments could corner the market. CustomReports will identify which candidates are on the market or in development that coincide with your chosen target. We will also look at pharmaceutical trends, both with respect to drug development and patent activity, to determine whether the field is emerging, stable or mature.
Case study 3 (an extract from "Angiotensin ligands for CNS disorders") click here

Market analyses: Of course competition is only one side of the story. Your company may have identified an effective COPD treatment but what would be the commercial value of such a molecule? To address this issue we will draw on public domain and proprietary market analysis data to estimate the market for candidates that match your chosen profile. You may also ask yourself when your company's therapeutic candidates will hit the market? This question is by nature difficult to address and depends not only on in house development speed but also on the candidate that you are developing. Through access to proprietary databases our analysts are able to estimate time-frames. For example, we can analyze development data on advanced or launched PDE5 inhibitors to determine how long it will take for your inhibitor to reach the market. Although CustomReports cannot give you exact answers you will have sufficient information to formulate a reliable business plan.
Case study 4 (an extract from "Angiotensin ligands for CNS disorders") click here

Strategic direction. CustomReports will provide you will information required for target selection, but how will your company go about target development. An appropriate screening architecture is a must and reports therefore offer a complete analysis by providing a suggested screening architecture.
Case study 5 (an extract from "Angiotensin ligands for CNS disorders") click here

In short, CustomReports deliver a comprehensive, rapid and expert service to all involved in drug development. If you or you company requires further information on how we can help streamline your target selection process please contact us using the feedback form below

Parties with an interest in the production of a Custom Report are invited to contact BioPortfolio who will put you in touch with LeadDiscovery:

Email: Peter D Barfoot - peter.barfoot@bioportfolio.com

Please provide your full contact details and your general area of interest.

Interested in adding commercial value to your research, technology or products?

LeadDiscovery and BioPortfolio aims to provide reliable, insightful analysis on the biotechnology industry. However, this information is provided "as is" and no representations or warranties either express or implied of completeness, accuracy, or of any other nature are made with respect to this information. This information is neither an offer to sell nor a solicitation to buy the securities of any company. This information contains forward-looking statements, which involve risks and uncertainties which may not be listed. The biotechnology industry is an emerging industry and the securities of the companies mentioned in this report have a very high degree of risk and volatility. For this reason, this information is supplied on the condition that the reader will make his or her own determination as to its suitability for any purpose prior to any use of this information. The employees and officers of LeadDiscovery and BioPortfolio may hold positions in some or all of the stocks discussed in this report.

This abstract has been produced by LeadDiscovery Ltd. Founded by life scientists for life scientists we aim to help industry identify cutting edge drug discovery options and academic/biotech institutions maximize the potential of their research. Abstracts strictly reflect the opinion of LeadDiscovery's editorial panel. While all reasonable efforts are made to ensure the accuracy of information provided LeadDiscovery and the publisher BioPortfolio, takes no responsibility for incorrect or misleading information. LeadDiscovery is designed for educational and drug development purposes only and is not intended or designed to offer medical advice or advice of any sort, and must not be used for such purpose. The information provided through LeadDiscovery and BioPortfolio should not be used for diagnosing or treating a health problem or a disease and no reliance should be placed on any information contained in this abstract or elsewhere on LeadDiscovery's and BioPortfolio's website. It is not intended to be a substitute for professional care. If you have or suspect you may have a health problem, you should consult your physician or other health care provider.

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.